Page 176 - Educacional Ponenecias Congreso SEHH-STH 2020

mitogens in chronic lymphocytic leukemia with “normal” FISH: correlations
with clinicobiologic parameters. Blood. 2012;119(10):2310-3.
15. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic
syndromes. Blood. 1997;89:2079-88.
16. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et
al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children’s Leukaemia Working Parties. Blood. 1998;92:2322-33.
17. Badoux XC, Keating MJ, Wang X, O’Brien SM, Ferrajoli A, Faderl S, et al. Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood. 2011;117:3016-24.
18. Baliakas P, Iskas M, Gardiner A, Davis Z, Plevova K, Nguyen-Khac F, et al. Chromosomal translocations and karyotype complexity in chronic lymphocytic leukemia: a systematic reappraisal of classic cytogenetic data. Am J Hematol. 2014 Mar;89(3):249-55.
19. Herling CD, Klaumünzer M, Rocha CK, Altmüller J, Thiele H, Bahlo J, et al. Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy. Blood. 2016;128:395-404.
20. Thompson PA, O’Brien SM, Wierda WG, Ferrajoli A, Stingo F, Smith SC, et al. Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. Cancer. 2015;121(20):3612-21.
21. Chanan-Khan A, Cramer P, Demirkan F, Fraser G, Silva RS, Grosicki S, et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma
(HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol.
2016;17(2):200-11.
22. Kreuzer KA, Furman RR, Stilgenbauer S, Dubowy RL, Kim Y, Munugalavadla V,
et al.The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab. Leukemia. 2020;34:296-300.
23. Blanco G, Puiggros A, Baliakas P, Athanasiadou A, García-Malo M, Collado R, et al. Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations. Oncotarget. 2016;7:80916-24.
24. Baliakas P, Puiggros A, Xochelli A, Sutton LA, Nguyen-Khac F, Gardiner A, et al. Additional trisomies amongst patients with chronic lymphocytic leukemia carrying trisomy 12: the accompanying chromosome makes a difference. Haematologica. 2016;101(7):e299-e302.
25. Ramos S, Puiggros A, Bea S, Bougeon S, Larrayoz MJ, Clot G, et al. Chromosome banding analysis versus genomic microarrays: a comparison of methods for genomic complexity risk stratification in chronic lymphocytic leukemia patients with complex karyotype. Blood. 2019;134(Supplement_1):4287.
26. Mato AR, Thompson M, Allan JN, Brander DM, Pagel JM, Ujjani CS, et al. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. Haematologica. 2018;103(9):1511-7.
27. Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379(26):2517-28.
28. Abrisqueta P, Bosch F. Venetoclax-obinutuzumab: harnessing complexity. Blood. 2020;135(11):788-9.
29. Al-Sawaf O, Lilienweiss E, Bahlo J, Robrecht S, Fink AM, Patz M, et al. High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia. Blood. 2020;135(11):866-70.
LXII Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia / Ponencias
176